Gujarat Themis Biosyn Ltd Forensic Report - SOIC x StockScans Report

as of Sep 2026

Gujarat Themis Biosyn's record is clean on its face: seven consecutive unqualified audit opinions, modest and declining contingent liabilities, and no regulator action beyond a single paid BSE penalty. The story of the last two years, however, is a deliberate transformation: a debt-free, dividend-paying fermentation business is being rebuilt into a leveraged, acquisition-funded expansion, with the funding mix for roughly ₹3,000 crore of deals still undecided and the Managing Director admitting projects are "late by almost about a year."

Key findings

  1. A debt-free business is pivoting into leveraged, acquisition-funded expansion Major - Gross block including capital work-in-progress rose from ₹62 crore in FY23 to ₹435 crore in FY26, and the new Vapi plant alone cost over ₹200 crore. On 23 April 2026 the company agreed to buy Sanofi's anti-TB brands for EUR 158 million, and on 22 May 2026 to buy MicroBiopharm Japan for about ₹1,300 crore, with no funds transferred for either as of approval. The MD says the equity raise is "up to INR1,000 crores" while the debt amount "remains undecided," and that projects are "late by almost about a year".
  2. Debt capacity expanded from ₹100 crore to ₹3,500 crore, with ratings on watch Major - Debt-to-equity climbed from zero in FY24 to 0.56 in FY26, and non-current borrowings rose from ₹29.6 crore to ₹128.1 crore in one year. Members are asked to raise the borrowing limit from ₹100 crore to ₹3,500 crore, and the Board seeks authority for up to ₹1,500 crore in NCDs. On 15 July 2026, CARE Ratings placed the company's bank facilities on Rating Watch with Negative Implications, noting the \~₹3,000 crore acquisitions are \~10x tangible net worth and that timely completion of a ₹1,000 crore QIP is critical.
  3. Related-party dealings with promoter-group Themis Medicare have escalated sharply Major - Trade receivables from Themis Medicare, which holds 23.19% of GTBL and shares three directors, surged from ₹3.86 lakh to ₹8.66 crore in one year. Shareholders are asked to approve a ₹50 crore related-party limit for FY2026-27, equal to 33.33% of GTBL's standalone turnover, with no bidding process. The 4 Sep 2026 AGM notice also seeks approval for related-party borrowing up to ₹450 crore and guarantees up to ₹1,000 crore.
  4. Promoter pay rose, the promoter holding company encumbered its entire stake, and public institutions voted against Major - The Chairman and his son each drew ₹66 lakh commission in FY2025-26, and the son was re-designated Managing Director at ₹10 lakh per month basic salary. Promoter Pharmaceutical Business Group encumbered its entire 47.02% stake on 29 June 2026, on top of a direct pledge of 2.34%. At the 5 June 2026 postal ballot, public institutions voted 99.95% against both resolutions while promoters voted 100% in favour.
  5. Revenue is concentrated in two customers, and receivables quality is deteriorating Major - Revenue fell from ₹168.55 crore in FY2023-24 to ₹143.26 crore in FY2024-25 to ₹120.91 crore in FY2025-26. The top customer's share swung from ₹103.87 crore to ₹79.63 crore to ₹97.57 crore over three years, following ₹65.06 crore in FY2022-23. The doubtful-debt provision increased from ₹10.00 lakh to ₹20.18 lakh in FY2026, and the credit period was extended from 45-60 days to 45-90 days.
  6. A three-tier offshore holding chain was built in weeks to buy MicroBiopharm Japan Minor - Having had no subsidiary for years, the company incorporated Themis Biosyn Japan on 19 May 2026, Themis Biosyn Ireland on 29 May 2026, and a third tier on 16 June 2026. The chain exists to acquire MicroBiopharm Japan, which reported estimated revenue of approximately ₹570 crore for FY2026E. The structure is complex but fully disclosed, and the acquisition is stated not to be a related-party transaction.
  7. Clean opinions on financials, with audit-trail qualifications Minor - GMJ & Co issued unqualified opinions on the standalone Ind AS financial statements for each year from FY2020 through FY2026. The FY2024 and FY2025 Section 143(3) proper-books opinions were qualified because the audit-trail feature was not enabled throughout FY2024 for all relevant transactions and from April 1 to July 24, 2024 in FY2025. The FY2026 report confirms the feature operated from July 25, 2024 with no tampering found. A single FY2020 CSR spending lapse is the only other procedural issue.
  8. One paid BSE penalty is the only regulator action in seven years Minor - BSE levied a penalty for delaying the bonus-issue implementation beyond the stipulated two-month period; the fine was paid and trading approval received from 27 August 2024. Every Corporate Governance report from FY2020 through FY2026 states no other penalties or strictures were imposed.
  9. Contingent liabilities are modest and declining Clean - Contingent liabilities fell from 4.71 crore in FY2025 to 3.36 crore in FY2026, and the company states no pending litigation is expected to materially affect its financial position. An arbitration with Optimus Drugs was amicably settled with no penalty.

What to watch

Bottom line: This is a disclosed and audited record with a clean compliance history, but the company is mid-transformation. The risk is concentrated in one place: the funding and execution of roughly ₹3,000 crore of acquisitions against a tangible net worth one-tenth that size, with the mix of debt and equity still undecided. Watch the shareholder votes and the rating agency's next move, and read the receivables line with the related-party growth in mind.